---
title: "Bank of America Securities raises the target price for SKB BIO to 479 yuan and lowers revenue forecasts"
description: "Bank of America Securities raised the target price for SKB BIO from 470 yuan to 479 yuan, while lowering the revenue forecasts for 2026 and 2027 by 5% and 6%, respectively. The company's sac-TMT drug "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275711706.md"
published_at: "2026-02-12T06:47:51.000Z"
---

# Bank of America Securities raises the target price for SKB BIO to 479 yuan and lowers revenue forecasts

> Bank of America Securities raised the target price for SKB BIO from 470 yuan to 479 yuan, while lowering the revenue forecasts for 2026 and 2027 by 5% and 6%, respectively. The company's sac-TMT drug was recently approved for the treatment of HR-positive/HER2-negative breast cancer and has been included in the national medical insurance catalog, but the annual treatment cost assumption has been adjusted downward due to medical insurance price adjustments. Bank of America Securities reiterated its "Neutral" rating on the company, believing that business progress is in line with expectations but faces intense competition

According to a research report by Bank of America Securities, SKB BIO-B (06990.HK) recently received approval from the National Medical Products Administration for its sac-TMT (TROP-2 ADC) to be used in the treatment of second-line and above HR-positive/HER2-negative breast cancer, marking the fourth indication approved for this drug in mainland China.

At the same time, the drug is indicated for third-line triple-negative breast cancer and third-line EGFR mutation non-small cell lung cancer, and has been included in the national medical insurance drug list since January of this year. However, due to price adjustments in the national medical insurance catalog, the bank has lowered its annual treatment cost assumptions for sac-TMT.

The bank has revised its revenue forecasts for 2026 and 2027 down by 5% and 6% respectively, raising the target price from 470 yuan to 479 yuan, and reiterating a "neutral" rating, reflecting that business progress is in line with expectations but is offset by increasingly fierce competition

### Related Stocks

- [06990.HK - SKB BIO-B](https://longbridge.com/en/quote/06990.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sichuan Kelun-Biotech Receives NMPA Approval for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administratio | [Link](https://longbridge.com/en/news/275096325.md) |
| Collage Becomes the First Benefits-Connected HR Platform in Canada to Embed Payroll, Powered by Nmbr | Collage has launched Collage Payroll, becoming the first benefits-connected HR platform in Canada to embed payroll, in p | [Link](https://longbridge.com/en/news/276121845.md) |
| REG - Midwich Group PLC - CFO Appointment – Additional Information | Midwich Group PLC has announced the appointment of a new Chief Financial Officer (CFO). The announcement includes a comp | [Link](https://longbridge.com/en/news/276328871.md) |
| Boxing-Floyd Mayweather to come out of retirement - again | Floyd Mayweather, the former multi-weight world boxing champion, is set to come out of retirement for his first official | [Link](https://longbridge.com/en/news/276504029.md) |
| Barclays Remains a Buy on BorgWarner (BWA) | Barclays analyst Dan Levy has maintained a Buy rating on BorgWarner (BWA) with a price target of $70.00, while the stock | [Link](https://longbridge.com/en/news/276534773.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.